Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right.
If you have questions about MD Anderson’s appointment process, our
information page may be the best place to start.
Find information and resources for current and returning patients.
Learn about clinical trials at MD Anderson and search our database for open studies.
Cancer Prevention Center
The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Your gift will help support our mission to end cancer and make a difference in the lives of our patients.
myMDAnderson for Physicians
Our personalized portal helps you refer your patients and communicate with their MD Anderson care team.
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.
Apply to SHP
Choose from 12 allied health programs at School of Health Professions.
Learn about our graduate medical education residency and fellowship opportunities.
B-Cell Lymphoma Moon Shot™
The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies.
Amy Heimberger, M.D., presentation at the European Association of
Neuro-Oncology meeting, 2012
Ling-Yuan Kong, M.D. Ph.D, presentation at the Society of Neuro-Oncology
Jun Wei, M.D., Ph.D, presentation at the Society of Neuro-Oncology
Amy Heimberger, M.D., presentation at the American Society of Clinical
Oncology meeting, 2006
Clinical Cancer Research
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB
A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients
Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB
A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells
Kong L-Y, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer Jr GE, Sampson JH, Priebe W, Heimberger AB
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
Heimberger AB, Reina-Ortiz C, Yang DS, Sun W, Abou-Ghazal M, Qiao W, Hiraoka N, Fuller GN
The incidence, correlation with tumor infiltrating inflammation, and prognosis of p-STAT3 expression in human gliomas
Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-K, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB
Clinical Cancer Research
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response
Kong LY, Wu A, Doucette T, Wei J, Priebe W, Fuller G, Qiao W, Sawaya R, Rao G, Heimberger AB
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Heimberger AB
Journal of Clinical Oncology
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III (EGFRvIII) peptide vaccination in patients with newly-diagnosed glioblastoma (GBM)
Heimberger AB*, Sampson JH*, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RL, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh J, Bigner DD (*Co-lead authors)
Molecular Cancer Therapeutics
Glioblastoma cancer-initiating cells inhibit T cell proliferation and effector responses by the STAT3 pathway
Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon II JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh J, Bigner DD, Heimberger AB
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma
de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB
Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma
Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bogler O, Heimberger AB, Rao G
Cancer Immunology Research
Immune heterogeneity of glioblastoma subtypes: Extrapolation from the cancer genome atlas
Doucette TA, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma
Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB
Journal of the National Cancer Institute
Effect of miR-142-3p inhibits the M2 macrophage and exerts therapeutic efficacy against murine glioblastoma
Xu S, Wei J, Wang F, Kong LY, Ling XY, Doucette T, Yang Y, Yaghi N, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy
Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas
Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S
PD-L1 expression and prognostic impact in glioblastoma
Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB